NCT06932068View on ClinicalTrials.gov

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab (QL1706)

5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.

DRUG

Oxallplation

130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.

DRUG

Capectitabine Tablets

1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER